Update on systemic sclerosis

Current Allergy and Asthma Reports

Volumn 15, Issue 5, 2015, Pages

  McCray, Courtney J ^a   Mayes, Maureen D ^a  

^a UNIVERSITY OF TEXAS MEDICAL SCHOOL   (United States)

Author keywords

Antinuclear antibody negative systemic sclerosis; Mimics; Systemic sclerosis; Therapeutics

Indexed keywords

ABATACEPT; ANTINUCLEAR ANTIBODY; AZATHIOPRINE; BIOLOGICAL PRODUCT; CALCIUM CHANNEL BLOCKING AGENT; COLLAGEN TYPE 1; CYCLOPHOSPHAMIDE; ENDOTHELIN RECEPTOR ANTAGONIST; HYDROXYCHLOROQUINE; IMATINIB; IVABRADINE; MACITENTAN; METHOTREXATE; MYCOPHENOLATE MOFETIL; PENICILLAMINE; PHOSPHODIESTERASE V INHIBITOR; PILOCARPINE; PLACEBO; PREDNISONE; PROSTAGLANDIN; PROSTANOID; PROTEIN TYROSINE KINASE INHIBITOR; PROTON PUMP INHIBITOR; RELAXIN; RIOCIGUAT; RITUXIMAB; SALIVA SUBSTITUTE; TOCILIZUMAB; TUMOR NECROSIS FACTOR ALPHA INHIBITOR; UNINDEXED DRUG;

ARTICLE; AUTOLOGOUS STEM CELL TRANSPLANTATION; CAPILLAROSCOPY; DISEASE CLASSIFICATION; DISEASE EXACERBATION; EDEMA; FINGER ULCER; GASTROESOPHAGEAL REFLUX; GASTROINTESTINAL DISEASE; HUMAN; INTESTINAL DYSMOTILITY; LUNG DISEASE; LUNG TRANSPLANTATION; MALIGNANT NEOPLASTIC DISEASE; MYOSITIS; PHASE 1 CLINICAL TRIAL (TOPIC); PHASE 2 CLINICAL TRIAL (TOPIC); PHASE 3 CLINICAL TRIAL (TOPIC); PRACTICE GUIDELINE; PULMONARY HYPERTENSION; RANDOMIZED CONTROLLED TRIAL (TOPIC); RASH; RAYNAUD PHENOMENON; RHEUMATOID ARTHRITIS; SENSITIVITY ANALYSIS; SJOEGREN SYNDROME; SKIN CALCIFICATION; SKIN DISEASE; SYSTEMIC SCLEROSIS; TREATMENT PLANNING; UNSPECIFIED SIDE EFFECT; VASCULAR DISEASE; DIFFERENTIAL DIAGNOSIS; EARLY DIAGNOSIS; IMMUNOLOGY; SCLERODERMA, SYSTEMIC;

ANTIBODIES, ANTINUCLEAR; DIAGNOSIS, DIFFERENTIAL; EARLY DIAGNOSIS; HUMANS; SCLERODERMA, SYSTEMIC;

EID: 84942592577     PISSN: 15297322     EISSN: 15346315     Source Type: Journal    
DOI: 10.1007/s11882-015-0526-0     Document Type: Article

References (93)

1. Mayes MD et al. Prevalence, incidence, survival, and disease characteristics of systemic sclerosis in a large US population. Arthritis Rheum. 2003;48:2246-55.
2. Steen V, Domsic RT, Lucas M, Fertig N, Medsger Jr. TA. A clinical and serologic comparison of African American and Caucasian patients with systemic sclerosis. Arthritis Rheum. 2012;64:2986-94
3. LeRoy EC, Medsger Jr. TA. Criteria for the classification of early systemic sclerosis. J Rheumatol. 2001;28:1573-6.
4. Preliminary criteria for the classification of systemic sclerosis (scleroderma). Subcommittee for scleroderma criteria of the American Rheumatism Association Diagnostic and Therapeutic Criteria Committee. Arthritis Rheum. 1980; 23:581-90.
5. van den Hoogen F et al. 2013 classification criteria for systemic sclerosis: an American College of Rheumatology/European League against Rheumatism collaborative initiative. Arthritis Rheum. 2013;65:2737-47. Newest classification criteria for Systemic Sclerosis.
6. Alhajeri H, et al. The 2013 ACR/EULAR Classification Criteria for Systemic Sclerosis Out-perform the 1980 Criteria. Data from the Canadian Scleroderma Research Group. Arthritis Care Res. (Hoboken) 2014.
7. Avouac J et al. Preliminary criteria for the very early diagnosis of systemic sclerosis: results of a Delphi Consensus Study from EULAR Scleroderma Trials and Research Group. Ann Rheum Dis. 2011;70:476-81.
8. Wigley FM. Clinical practice. Raynaud’s Phenomenon. N Engl J Med. 2002;347:1001-8.
9. Koenig M et al. Autoantibodies and microvascular damage are independent predictive factors for the progression of Raynaud’s phenomenon to systemic sclerosis: a twenty-year prospective study of 586 patients, with validation of proposed criteria for early systemic sclerosis. Arthritis Rheum. 2008;58:3902-12.
10. Ho KT, Reveille JD. The clinical relevance of autoantibodies in scleroderma. Arthritis Res Ther. 2003;5:80-93.
11. Hamaguchi Y. Autoantibody profiles in systemic sclerosis: predictive value for clinical evaluation and prognosis. J Dermatol. 2010;37:42-53.
12. Salazar GA, Assassi S, Wigley F, Hummers LK, Varga M, Hinchcliff D, et al. Antinuclear Antibody Negative Systemic Sclerosis. Semin Arthritis Rheum. doi: 10.1016/j.semarthrit.2014. 11.006. This is the largest ANA negative SSc cohort to date.
13. Fett N, Werth VP. Update on morphea: part I. Epidemiology, clinical presentation, and pathogenesis. J Am Acad Dermatol. 2011;64: 217-28.
14. Dharamsi JW et al. Morphea in adults and children cohort III: nested case-control study-the clinical significance of autoantibodies in morphea. JAMA Dermatol. 2013;149:1159-65.
15. Shulman LE. Diffuse fasciitis with eosinophilia: a new syndrome? Trans Assoc Am Phys. 1975;88:70-86.
16. Antic M, Lautenschlager S, Itin PH. Eosinophilic fasciitis 30 years after-what do we really know? Report of 11 patients and review of the literature. Dermatology. 2006;213:93-101.
17. Rosenbloom AL. Limitation of finger joint mobility in diabetes mellitus. J Diabet Complicat. 1989;3:77-87.
18. Beers WH, Ince A, Moore TL. Scleredema adultorum of Buschke: a case report and review of the literature. Semin Arthritis Rheum. 2006;35:355-9
19. Hummers LK. Scleromyxedema. Curr Opin Rheumatol. 2014;26: 658-62.
20. Rongioletti F, Rebora A. Updated classification of popular mucinosis, lichen myxedematosus, and scleromyxedema. J Am Acad Dermatol. 2001;44:273-81.
21. Grobner T. Gadolinium-a specific trigger for the development of nephrogenic fibrosing dermopathy and nephrogenic systemic fibrosis? Nephrol Dial Transplant. 2006;21:1104-8.
22. Cowper SE et al. Scleromyxoedema-like cutaneous diseases in renal-dialysis patients. Lancet. 2000;356:1000-1.
23. Kowal-Bielecka O et al. EULAR recommendations for the treatment of systemic sclerosis: a report from the EULAR Scleroderma Trials and Research group (EUSTAR). Ann Rheum Dis. 2009;68: 620-8.
24. Walker KM, Pope J. Treatment of systemic sclerosis complications: what to use when first-line treatment fails-a consensus of systemic sclerosis experts. Semin Arthritis Rheum. 2012;42: 42-55. This paper presents treatment algorhithms for SSc based on expert opinion.
25. van den Hoogen FH et al. Comparison of methotrexate with placebo in the treatment of systemic sclerosis: a 24 week randomized double-blind trial, followed by a 24 week observational trial. Br J Rheumatol. 1996;35:364-72.
26. Pope JE et al. A randomized, controlled trial of methotrexate versus placebo in early diffuse scleroderma. Arthritis Rheum. 2001;44: 1351-8.
27. Derk CT et al. A prospective open-label study of mycophenolate mofetil for the treatment of diffuse systemic sclerosis. Rheumatology (Oxford). 2009;48:1595-9.
28. Le EN, Wigley FM, Shah AA, Boin F, Hummers LK. Long-term experience of mycophenolate mofetil for treatment of diffuse cutaneous systemic sclerosis. Ann Rheum Dis. 2011;70:1104-7.
29. Mendoza FA, Nagle SJ, Lee JB, Jimenez SA. A prospective observational study of mycophenolate mofetil treatment in progressive diffuse cutaneous systemic sclerosis of recent onset. J Rheumatol. 2012;39:1241-7.
30. Tashkin DP et al. Effects of 1-year treatment with cyclophosphamide on outcomes at 2 years in scleroderma lung disease. Am J Respir Crit Care Med. 2007;176:1026-34.
31. Hoyles RK et al. A multicenter, prospective, randomized, doubleblind, placebo-controlled trial of corticosteroids and intravenous cyclophosphamide followed by oral azathioprine for the treatment of pulmonary fibrosis in scleroderma. Arthritis Rheum. 2006;54: 3962-70.
32. Moazedi-Fuerst FC et al. Rituximab for systemic sclerosis: arrest of pulmonary disease progression in five cases. Results of a lower dosage and shorter interval regimen. Scand J Rheumatol. 2014;43:257-8.
33. Daoussis D et al. Effect of long-term treatment with rituximab on pulmonary function and skin fibrosis in patients with diffuse systemic sclerosis. Clin Exp Rheumatol. 2012;30:S17-22.
34. Smith V et al. Two-year results of an open pilot study of a 2-treatment course with rituximab in patients with early systemic sclerosis with diffuse skin involvement. J Rheumatol. 2013;40: 52-7.
35. Bosello SL et al. Long-term efficacy of B cell depletion therapy on lung and skin involvement in diffuse systemic sclerosis. Semin Arthritis Rheum. 2015;44:428-36.
36. Jordan S et al. Effects and safety of rituximab in systemic sclerosis: an analysis from the European Scleroderma Trial and Research (EUSTAR) group. Ann Rheum Dis. 2014. doi:10.1136/annrheumdis-2013-204522.
37. Burt RK et al. Autologous non-myeloablative haemopoietic stem-cell transplantation compared with pulse cyclophosphamide once per month for systemic sclerosis (ASSIST): an open-label, randomised phase 2 trial. Lancet. 2011;378:498-506.
38. van Laar JM et al. Autologous hematopoietic stem cell transplantation vs intravenous pulse cyclophosphamide in diffuse cutaneous systemic sclerosis: a randomized clinical trial. JAMA. 2014;311: 2490-8. First phase III randomized controlled trial looking at HSCT as a theraputic option for SSc.
39. Spiera RF et al. Imatinib mesylate (Gleevec) in the treatment of diffuse cutaneous systemic sclerosis: results of a 1-year, phase IIa, single-arm, open-label clinical trial. Ann Rheum Dis. 2011;70: 1003-9.
40. Khanna D et al. A one-year, phase I/IIa, open-label pilot trial of imatinib mesylate in the treatment of systemic sclerosis-associated active interstitial lung disease. Arthritis Rheum. 2011;63:3540-6.
41. Yilmaz N, Can M, Kocakaya D, Karakurt S, Yavuz S. Two-year experience with mycophenolate mofetil in patients with scleroderma lung disease: a case series. Int J Rheum Dis. 2014;17:923-8.
42. Simeon-Aznar CP et al. Effect of mycophenolate sodium in scleroderma-related interstitial lung disease. Clin Rheumatol. 2011;30:1393-8.
43. Fraticelli P et al. Low-dose oral imatinib in the treatment of systemic sclerosis interstitial lung disease unresponsive to cyclophosphamide: a phase II pilot study. Arthritis Res Ther. 2014;16:R144.
44. Rubin LJ et al. Bosentan therapy for pulmonary arterial hypertension. N Engl J Med. 2002;346:896-903.
45. Galie N et al. Sildenafil citrate therapy for pulmonary arterial hypertension. N Engl J Med. 2005;353:2148-57.
46. Badesch DB et al. Continuous intravenous epoprostenol for pulmonary hypertension due to the scleroderma spectrum of disease. A randomized, controlled trial. Ann Intern Med. 2000;132:425-34.
47. Ghofrani HA et al. Riociguat for the treatment of pulmonary arterial hypertension. N Engl J Med. 2013;369:330-40. This is a phase III randomized controlled trial showing benefit of new medication class for treatment of pulmonary arterial hypertension and chronic thromboembolic pulmonary hypertension.
48. Thompson AE, Shea B, Welch V, Fenlon D, Pope JE. Calcium-channel blockers for Raynaud’s phenomenon in systemic sclerosis. Arthritis Rheum. 2001;44:1841-7.
49. Matucci-Cerinic M et al. Bosentan treatment of digital ulcers related to systemic sclerosis: results from the RAPIDS-2 randomised, double-blind, placebo-controlled trial. Ann Rheum Dis. 2011;70:32-8.
50. Herrick AL et al. Modified-release sildenafil reduces Raynaud’s phenomenon attack frequency in limited cutaneous systemic sclerosis. Arthritis Rheum. 2011;63:775-82.
51. Wigley FM, Seibold JR, Wise RA, McCloskey DA, Dole WP. Intravenous iloprost treatment of Raynaud’s phenomenon and ischemic ulcers secondary to systemic sclerosis. J Rheumatol. 1992;19:1407-14.
52. Wigley FM et al. Intravenous iloprost infusion in patients with Raynaud phenomenon secondary to systemic sclerosis. A multicenter, placebo-controlled, double-blind study. Ann Intern Med. 1994;120:199-206.
53. Johnson SR, Feldman BM, Pope JE, Tomlinson GA. Shifting our thinking about uncommon disease trials: the case of methotrexate in scleroderma. J Rheumatol. 2009;36:323-9.
54. Panopoulos ST et al. Mycophenolate versus cyclophosphamide for progressive interstitial lung disease associated with systemic sclerosis: a 2-year case control study. Lung. 2013;191:483-9.
55. Tashkin DP et al. Cyclophosphamide versus placebo in scleroderma lung disease. N Engl J Med. 2006;354:2655-66.
56. Nadashkevich O, Davis P, Fritzler M, Kovalenko W. A randomized unblinded trial of cyclophosphamide versus azathioprine in the treatment of systemic sclerosis. Clin Rheumatol. 2006;25:205-12.
57. Paone C et al. Twelve-month azathioprine as maintenance therapy in early diffuse systemic sclerosis patients treated for 1-year with low dose cyclophosphamide pulse therapy. Clin Exp Rheumatol. 2007;25:613-6
58. Prey S et al. Imatinib mesylate in scleroderma-associated diffuse skin fibrosis: a phase II multicentre randomized double-blinded controlled trial. Br J Dermatol. 2012;167:1138-44.
59. Cipriani P et al. Stem cells in autoimmune diseases: Implications for pathogenesis and future trends in therapy. Autoimmun Rev. 2013;12:709-16.
60. ClinicalTrials.gov: Scleroderma: cyclophosphamide or transplantation (SCOT). https://clinicaltrials.gov/ct2/show/NCT00114530
61. Mukerjee D et al. Prevalence and outcome in systemic sclerosis associated pulmonary arterial hypertension: application of a registry approach. Ann Rheum Dis. 2003;62:1088-93.
62. McLaughlin VV et al. Treatment goals of pulmonary hypertension. J Am Coll Cardiol. 2013;62:D73-81.
63. Kovacs G et al. Pulmonary arterial hypertension therapy may be safe and effective in patients with systemic sclerosis and borderline pulmonary artery pressure. Arthritis Rheum. 2012;64:1257-62.
64. Johnson SR, Brode SK, Mielniczuk LM, Granton JT. Dual therapy in IPAH and SSc-PAH. A qualitative systematic review. Respir Med. 2012;106:730-9.
65. Pulido T et al. Macitentan and morbidity and mortality in pulmonary arterial hypertension. N Engl J Med. 2013;369:809-18.
66. Correale M, Montrone D, Ieva R, Di BM, Brunetti ND. Ivabradine in systemic sclerosis related pulmonary arterial hypertension. Eur J Intern Med. 2012;23:e210-1.
67. Correale M, Montrone D, Biase MD, Brunetti ND. Safe and well-tolerated treatment with ivabradine in systemic sclerosis affected by pulmonary hypertension. Clin Res Cardiol. 2012;101:593-4.
68. Shitrit D et al. Lung transplantation in patients with scleroderma: case series, review of the literature, and criteria for transplantation. Clin Transplant. 2009;23:178-83.
69. Saggar R et al. Systemic sclerosis and bilateral lung transplantation: a single centre experience. Eur Respir J. 2010;36:893-900.
70. Khan IY et al. Survival after lung transplantation in systemic sclerosis. A systematic review. Respir Med. 2013;107:2081-7.
71. Cozzi F et al. Low occurrence of digital ulcers in scleroderma patients treated with bosentan for pulmonary arterial hypertension: a retrospective case-control study. Clin Rheumatol. 2013;32:679-83.
72. Lam GK, Hummers LK, Woods A, Wigley FM. Efficacy and safety of etanercept in the treatment of scleroderma-associated joint disease. J Rheumatol. 2007;34:1636-7.
73. Omair MA, Phumethum V, Johnson SR. Long-term safety and effectiveness of tumour necrosis factor inhibitors in systemic sclerosis patients with inflammatory arthritis. Clin Exp Rheumatol. 2012;30: S55-9.
74. Elhai M et al. Outcomes of patients with systemic sclerosis-associated polyarthritis and myopathy treated with tocilizumab or abatacept: a EUSTAR observational study. Ann Rheum Dis. 2013;72:1217-20.
75. Kirby DF, Chatterjee S. Evaluation and management of gastrointestinal manifestations in scleroderma. Curr Opin Rheumatol. 2014;26:621-9.
76. Hansi N et al. Consensus best practice pathway of the UK scleroderma study group: gastrointestinal manifestations of systemic sclerosis. Clin Exp Rheumatol. 2014;32:S1-21.
77. Wollheim FA, Akesson A. Management of intestinal involvement in systemic sclerosis. J Clin Rheumatol. 2007;13:116-8.
78. Swanson E, Mahgoub A, MacDonald R, Shaukat A. Medical and endoscopic therapies for angiodysplasia and gastric antral vascular ectasia: a systematic review. Clin Gastroenterol Hepatol. 2014;12: 571-82.
79. Bures J et al. Small intestinal bacterial overgrowth syndrome. World J Gastroenterol. 2010;16:2978-90.
80. Frech TM et al. Probiotics for the treatment of systemic sclerosisassociated gastrointestinal bloating/distention. Clin Exp Rheumatol. 2011;29:S22-5.
81. Baron M, Hudson M, Steele R. Malnutrition is common in systemic sclerosis: results from the Canadian scleroderma research group database. J Rheumatol. 2009;36:2737-43.
82. Berger RG, Featherstone GL, Raasch RH, McCartney WH, Hadler NM. Treatment of calcinosis universalis with low-dose warfarin. Am J Med. 1987;83:72-6.
83. Sharma NL, Mahajan VK, Ranjan N, Sharma VC, Gupta M. Systemic sclerosis sine scleroderma and calcinosis cutis: report of a rare case. Clin Rheumatol. 2010;29:215-9.
84. Penate Y et al. Calcinosis cutis associated with amyopathic dermatomyositis: response to intravenous immunoglobulin. J Am Acad Dermatol. 2009;60:1076-7.
85. Daoussis D, Antonopoulos I, Liossis SN, Yiannopoulos G, Andonopoulos AP. Treatment of systemic sclerosis-associated calcinosis: a case report of rituximab-induced regression of CRESTrelated calcinosis and review of the literature. Semin Arthritis Rheum. 2012;41:822-9.
86. Tosounidou S, MacDonald H, Situnayake D. Successful treatment of calcinosis with infliximab in a patient with systemic sclerosis/ myositis overlap syndrome. Rheumatology (Oxford). 2014;53: 960-1.
87. Taborn J, Bole GG, Thompson GR. Colchicine suppression of local and systemic inflammation due to calcinosis universalis in chronic dermatomyositis. Ann Intern Med. 1978;89:648-9.
88. Chamberlain AJ, Walker NP. Successful palliation and significant remission of cutaneous calcinosis in CREST syndrome with carbon dioxide laser. Dermatol Surg. 2003;29:968-70.
89. Sultan-Bichat N et al. Treatment of calcinosis cutis by extracorporeal shock-wave lithotripsy. J Am Acad Dermatol. 2012;66:424-9.
90. ClinicalTrials.gov: Comparison of Therapeutic Regimens for Scleroderma Interstitial Lung Disease (The Scleroderma Lung Study II). https://www.clinicaltrials.gov/ct2/results?term=NCT00883129
91. ClinicalTrail.gov: A Study of RoActemra/Actemra (Tocilizumab) Versus Placebo in Patients With Systemic Sclerosis. http://clinicaltrials.gov/ct2/show/NCT01532869?term=tocilizumab+AND+systemic+sclerosis&rank=1
92. ClinicalTrials.gov: Belimumab for the Treatment of Diffuse Cutaneous Systemic Sclerosis. http://clinicaltrials.gov/ct2/show/NCT01670565?term=belimumab+AND+systemic+sclerosis&rank=1
93. ClinicalTrials.gov: Rituximab in Systemic Sclerosis (RECOVER). http://clinicaltrials.gov/ct2/show/NCT01748084?term=rituximab+AND+systemic+sclerosis&rank=1